CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...

NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 is Intellia's first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic On track to dose the first patient in 2H 2024 CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 is Intellia's first wholly owned CRISPR-based in vivo targeted gene insertion candidate to advance into the clinic On track to dose the first patient in 2H 2024 "NTLA-3001 is a groundbreaking in vivo CRISPR-based gene insertion candidate designed to durably produce functional AAT protein at normal levels after ...

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][4][11]. Earnings Estimates and Stock Movement - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [3]. Intellia Therapeutics' Earnings Outlook - Intellia Therapeutics is projected to earn -$5.08 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 6.3% [7]. - Over the past three months, the Zacks Consensus Estimate for Intellia has increased by 10.5%, indicating a positive trend in earnings estimates [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [6][12]. - The upgrade of Intellia Therapeutics to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for stock price appreciation in the near term [9][12].

Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative. So long as humans are afflicted by various diseases, there will be a need for advanced pharmaceutical solutions. Therefore, money has been flowing into the broader biotechnology space and that will probably not fade anytime soon. Plus, as an American investor, you're in luck. Just the U.S. sector itself reached a valuation of $246.18 billion last year. By 2033, the domes ...

NEW YORK, July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you own NTLA please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. The consultation and case are free with n ...

Company Overview - Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics, with its lead candidate NTLA-2001 targeting transthyretin (ATTR) amyloidosis [3] - NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron, where Regeneron shares 25% of the development costs and commercial profits [3][11] Recent Developments - The company appointed Edward Dulac as the new CFO, effective July 22, 2024, succeeding Glenn Goddard, who will step down on June 30, 2024 [1][9][10] - Intellia reported encouraging long-term data from the phase I portion of its study evaluating NTLA-2002 for hereditary angioedema (HAE) [4][13] Financial Performance - Year to date, shares of Intellia have declined by 24.8%, while the industry has seen a decline of 4.6% [2] - The company currently holds a Zacks Rank 3 (Hold) [6] Clinical Trials and Milestones - NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy and ATTR amyloidosis with cardiomyopathy, with the phase III MAGNITUDE study ongoing [12] - Several clinical milestones are expected later in the year, which may impact the company's growth trajectory [5]

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. "Ed's deep financial and business development experience at cli ...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024. Mr. Dulac will succeed Glenn Goddard who will step down from his role effective June 30, 2024. Mr. Dulac is a highly accomplished biotechnology business leade ...

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at t ...